Families and advocacy groups from dozens of countries around the world are urging Vertex Pharmaceuticals (VRTX) to take several steps to widen global access to its cystic fibrosis medicines and avoid “fatal inequality.”
In an open letter, they suggested providing the drugs at affordable prices, offering the medicines on a so-called compassionate use basis where the drugs are not yet available, or issuing licenses to generic makers in countries where the company does not plan to supply the treatments any time soon.
About the Author Reprints
